TriSalus Reports Q3 2026 Revenue Growth Driven by TriNav System Adoption
TriSalus (TLSI) reported third-quarter 2026 revenue of $12.9 million, an 11.3% increase year-over-year, fueled by rising sales of its TriNav drug delivery system. The company achieved a gross margin of 86.2%, up from 83.5% in the previous year, citing manufacturing efficiencies and lower per-unit costs. While net loss per share improved significantly to $0.15 compared to $0.96 last year, management noted that revenue growth fell slightly below internal expectations due to a transition period within their commercial sales organization. Looking ahead, TriSalus expects full-year 2026 revenue between $46 million and $48 million. The company is positioned for significant reimbursement tailwinds starting January 1, 2027, when HCPCS Code C8004 payments are expected to increase by 76%. With $41.1 million in cash reserves, management believes they have sufficient liquidity to fund their current strategic growth plan and expand their footprint in the liver embolization market.
Topics: Drug Delivery Technology Financial Guidance Gross Margin Improvement Revenue Growth